Application of tanshinone and NPC1L1 inhibitor or drug

Tanshinone compounds, as inhibitors of the NPC1L1 receptor protein, have solved the problem of the lack of effective drugs in the existing technology, and have provided a new treatment option by significantly inhibiting cholesterol absorption and improving non-alcoholic fatty liver disease.

CN122398818APending Publication Date: 2026-07-17DALIAN INSTITUTE OF CHEMICAL PHYSICS CHINESE ACADEMY OF SCIENCES
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
DALIAN INSTITUTE OF CHEMICAL PHYSICS CHINESE ACADEMY OF SCIENCES
Filing Date
2025-01-15
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

There is a lack of effective NPC1L1 target inhibitors in the current technology, especially for the treatment of diseases such as hyperlipidemia, atherosclerosis, obesity, non-alcoholic fatty liver disease and tumors.

Method used

Tanshinone compounds and their combinations are used as NPC1L1 receptor protein inhibitors to develop tablets, capsules, drops, granules or injections for the preparation of drugs to treat NPC1L1 target-related diseases.

Benefits of technology

Tanshinone compounds significantly inhibit NPC1L1-mediated cholesterol absorption and improve high-fat diet-induced non-alcoholic fatty liver disease, providing a new drug option for the treatment of NPC1L1-targeted diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122398818A_ABST
    Figure CN122398818A_ABST
Patent Text Reader

Abstract

本发明提供了丹参酮在制备NPC1L1靶点抑制剂和制备治疗NPC1L1靶点相关疾病的药物中的应用，属于医药技术领域。本发明首次报道了丹参酮类化合物能够显著抑制NPC1L1介导的胆固醇的吸收，因此可用于制备NPC1L1靶点的抑制剂。同时，这类化合物通过抑制NPC1L1明显改善了高脂饮食诱导小鼠的非酒精性脂肪肝，因此可用于制备治疗NPC1L1靶点相关疾病的药物。本发明为NPC1L1靶点及相关疾病提供了新的抑制剂和治疗药物，具有十分重要的应用潜力。
Need to check novelty before this filing date? Find Prior Art